Diagnosing risk of cardiovascular complications using natiuretic peptides
US7655416B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 13, 2006 |
| Grant date | Feb 2, 2010 |
| Priority date | — |
| Expiry date | Feb 21, 2027 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/81
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the risk of suffering from a cardiovascular complication, particularly heart disease or acute coronary syndrome, as a consequence of cardiotoxic medication, in particular chemotherapeutics, including anthracyclines. In particular, the invention relates to a method for diagnosing the risk of a patient who is going to receive cardiotoxic medication of suffering from a cardiovascular complication as a consequence of the cardiotoxic medication, comprising the steps of (a) taking a body fluid or tissue sample, and (b) measuring, preferably in vitro, the level of a cardiac hormone. Preferred cardiac hormones in the context of the present invention are ANP, NT-proANP, BNP, and NT-proBNP.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.